Skip to main content
SpringerLink
Log in

Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Methylenetetrahydrofolate reductase (MTHFR) is one of the most critical enzyme in folic acid metabolism, and it converts 5,10-MTHF to 5-MTHF. 5,10-MTHF is required for conversion of uridilate to thymidylate. On the other side, MTHFR enzyme causes methylation of homocysteine into methionine, leading to methylation of DNA. Chemotherapeutic agents have different effects, but DNA is the target for most of them. Because folate is the cornerstone in DNA synthesis, we analysed herein if the polymorphisms in MTHFR gene can alter the susceptibility of lymphoproliferative disease risk and if it has an effect on chemotherapy response. One hundred fifty-six patients with lymphoid malignancies and 82 healthy controls were included into the study. Neither gene frequencies nor allel frequencies were found to increase lymphoproliferative disease risk significantly in both overall group and subgroups. Although it was not statistically significant, we found a 2.7-fold increased risk in acute lymphocytic leukaemia (ALL)/Burkitt lymphoma patients with TT genotype [odds ratio (OR), 2.7; 95% confidence interval (CI), 0.88–8.2] than CC genotype but a 1.7-fold decreased risk with TT genotype in diffuse large B-cell lymphoma (DLBCL; OR, 0.58; 95% CI, 0.17–1.88) and a 1.8-fold decreased risk in Hodgkin’s lymphoma with TT genotype (OR, 0.55; 95% CI, 0.10–2.87) than CC genotype. The chemotherapy response was analysed in DLBCL, Hodgkin’s lymphoma and ALL/Burkitt’s lymphoma because these patients received standard chemotherapy protocols. No significant difference was detected between responder and non-responders according to MTHFR T677C polymorphism, but the patients who had TT genotype respond 1.75-fold worse than CC (OR, 0.57; 95% CI, 0.07–4.64) in ALL patients (p=0.59), and in DLBCL, CT genotype revealed a 1.8-fold worse response than CC genotype (OR, 0.54; 95% CI, 0.17–1.7), but TT genotype revealed 2.6-fold better response rates than patients with CC genotype (OR, 2.6; 95% CI, 0.26–26.8). As a conclusion, MTHFR C677T polymorphism does not increase the risk of lymphoproliferative disease, and it does not have an effect on chemotherapy response significantly; however, the patients with TT genotype have a slightly increased risk for ALL, and they also respond worse than CC genotype. TT genotype slightly decreases the risk of DLBCL, and the patients have much favorable response rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ames BN (2001) DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res 475:7–20

    PubMed  CAS  Google Scholar 

  2. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T (2005) Methylenetetrahydofolate reductase polymorphism and therapy response in pediatric acute lymphoblast leukemia. Cancer Res 65:2482–2487

    Article  PubMed  CAS  Google Scholar 

  3. Aslanidis C, Schmitz G (2001) High speed methylenetetrahydrofolate reductase C→T 677 mutation detection on Light Cycler. In: Meuer S, Wittwer C, Nakagawara K (eds) Rapid cycle real-time PCR methods and applications. Springer, Berlin Heidelberg New York, pp 83–89

    Google Scholar 

  4. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SH, Everson RB, Ames BN (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implication for cancer and neuronal damage. Proc Natl Acad Sci USA 94:3290–3295

    Article  PubMed  CAS  Google Scholar 

  5. Chen J, Giovannucci EL, Hunter DJ (1999) MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among US men and women: an example of gene environment interactions in colorectal tumorigenesis. J Nutr 129:560–564

    Google Scholar 

  6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 18:1244

    Google Scholar 

  7. Cheson BD, Bennet JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642–4649

    Article  PubMed  Google Scholar 

  8. De Jonge R, Hooijberg JH, van Zelst BD, Jansen G, vanZantwijk CH, Kaspers GJL, Peters FGJ, Ravindranath Y, Pieters R, Lindemans J (2005) Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106:717–720

    Article  PubMed  CAS  Google Scholar 

  9. Duthie SJ (1999) Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 55:578–592

    Article  PubMed  CAS  Google Scholar 

  10. Ergül E, Sazcı A, Utkan Z, Cantürk NZ (2003) Polymorphisms in the MTHFR gene are associated with breast cancer. Tumor Biol 24:286–290

    Article  CAS  Google Scholar 

  11. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J (1997) Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18:2307–2311

    Article  PubMed  CAS  Google Scholar 

  12. Friso S, Choi SW, Girelli D, Mason JB, Dolnikowski GG, Bagley PJ, Olivieri O, Jacques PF, Rosenberg IH, Correcher R, Selhub J (2002) A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99:5606–5611

    Article  PubMed  CAS  Google Scholar 

  13. Frosst P, Blom HJ, Milos R, Goyett P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113

    Article  PubMed  CAS  Google Scholar 

  14. Gemmati D, Ongaro A, Scapoli GL, Della Porta M, Tognazzo S, Serino ML, Di Bona E, Rodeghiero F, Gilli G, Reverberi R, Caruso A, Pasello M, Pellati A, De Mattei M (2004) Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin’s lymphoma in adults. Cancer Epidemiol Biomarkers Prev 13:787–794

    PubMed  CAS  Google Scholar 

  15. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R (1994) Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 7:195–200

    Article  PubMed  CAS  Google Scholar 

  16. Hande KR (2004) Principles and pharmacology of chemotherapy. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds) Wintrobe’s clinical hematology, vol 2. Lippincott Williams &Wilkins, Philadelphia, pp 1945–1969

    Google Scholar 

  17. Jolivet J, Cowan KH, Curt GA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094–1104

    Article  PubMed  CAS  Google Scholar 

  18. Kim YI (2004) Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev 13:511–519

    PubMed  CAS  Google Scholar 

  19. Kım YI (2004) Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem 10:66–68

    Google Scholar 

  20. Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Moghrabi A, Sinnet D (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103:252–257

    Article  PubMed  CAS  Google Scholar 

  21. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A, Enno A (2003) Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin’s lymphoma or multiple myeloma. Br J Haematol 120:1051–1054

    Article  PubMed  CAS  Google Scholar 

  22. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, Kondoh E, Maeda S, Asakura S, Kaba S, Nakamura S, Seto M, Morishima Y, Tajima K (2001) Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97:3205–3209

    Article  PubMed  CAS  Google Scholar 

  23. Niclot S, Pruvot Q, Besson C, Savoy D, Macintyre E, Salles G, Brousse N, Varet B, Landais P, Taupin P, Junien C, Baudry-Bluteau D (2006) Implication of the folate–methionine metabolism pathways in susceptibility to follicular lymphomas. Blood 108:278–285

    Article  PubMed  CAS  Google Scholar 

  24. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G (1999) Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 96:12810–12815

    Article  PubMed  CAS  Google Scholar 

  25. Skibola C, Forrest SM, Coppede F, Agana L, Hubbard A, Smith MT, Bracci PM, Holly EA (2004) Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 104:2155–2162

    Article  PubMed  CAS  Google Scholar 

  26. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M (1999) methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 8:513–518

    PubMed  CAS  Google Scholar 

  27. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail SK, Keener CL, Li S, Liu H, Farin FM, Potter JD (2001) Pharmacogenetic of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98:231–234

    Article  PubMed  CAS  Google Scholar 

  28. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF, United Kingdom Childhood Cancer Study Investigators (2001) Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98:4004–4009

    Article  PubMed  CAS  Google Scholar 

  29. Wisberg I, Tran P, Christensen B, Sibani S, Rozen R (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172

    Article  Google Scholar 

  30. Zanrosso CW, Hatagima A, Emerenciano M, Ramos F, Figueiredo A, Felix TM, Segal SL, Guigliani R, Muniz MTC, Pombo-de-Oliveira MS (2006) The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leukemia Res 2006 30:477–481

    Article  CAS  Google Scholar 

  31. Zingg JM, Jones PA (1997) Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 18:869–882

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, School of Medicine, Akdeniz University, Antalya, Turkey

    A. Timuragaoglu

  2. Molecular Hematology Unit of Central Laboratory, School of Medicine, Akdeniz University, Antalya, Turkey

    S. Dizlek & N. Uysalgil

  3. Department of Statistics, School of Medicine, Akdeniz University, Antalya, Turkey

    O. Tosun

  4. Department of Hematology, School of Medicine, Gazi University, Ankara, Turkey

    K. Yamac

  5. Toros mah. 818 sok No: 10/2, 07070, Arapsuyu, Antalya, Turkey

    A. Timuragaoglu

Authors
  1. A. Timuragaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Dizlek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Uysalgil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O. Tosun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Yamac
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Timuragaoglu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Timuragaoglu, A., Dizlek, S., Uysalgil, N. et al. Methylenetetrahydrofolate reductase C677T polymorphism in adult patients with lymphoproliferative disorders and its effect on chemotherapy. Ann Hematol 85, 863–868 (2006). https://doi.org/10.1007/s00277-006-0175-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-006-0175-4

Keywords

Search

Navigation